AdvanTx – Two External Funding Opportunities Related to Drug Discovery for Faculty

AdvanTx would like to distribute two external corporate collaboration opportunities for faculty – the Johnson and Johnson Quickfire Challenge for Immune Mediated Diseases and a Beta Helix Protein Discovery Opportunity.

Johnson & Johnson Innovation QuickFire Challenge

DEADLINE: 01/14/2022

Johnson & Johnson Innovation LLC, in collaboration with Janssen Research & Development LLC, launches the Immunology Innovations QuickFire Challenge. Innovators with potential transformative solutions to help or aim to advance precision medicine approaches in immune-mediated diseases are welcome to apply.

Pathological areas specific to this challenge include gastroenterology, rheumatology, dermatology, fetal-maternal diseases, autoantibody-mediated diseases, and other immune-mediated diseases where a layered approach has the potential to ‘be transformational for patients.

The innovator (s) with the best idea, therapy or technology, or innovative approach will receive up to $ 500,000 in grants, access to the global Johnson & Johnson Innovation – JLABS (‘JLABS’) network and the mentoring experts through the Johnson & Johnson family of companies.

Interested innovators can find more detailed information on specific areas of interest and criteria by visiting the J&J website.

Opportunity to discover beta-helix proteins

The AdvanTx team recently learned that certain commercial parties are strategically focusing on the discovery of new drugs targeting beta-propellant proteins. This class of target proteins contains over 500 members with a conserved helix-like fold that are known to serve as structural scaffolds mediating interactions with proteins, nucleic acids and other biomolecules. Additionally, members of this protein family play functional roles in a diverse set of cellular processes including protein homeostasis, DNA repair, and cell cycle signaling. Certain drug discovery entities are particularly interested in exploring collaborations involving b-helices of great scientific and clinical interest.

The AdvanTx team is reaching out to researchers at UNC to determine if there are specific research labs that are actively studying specific members of this target class of proteins. A list of genes / proteins specific for helix b of high interest can be found here.

We encourage any UNC researcher working on genes / proteins on this list, or in the J&J opportunity, to contact the AdvanTx team ([email protected]) to discuss the project and potential avenues for collaboration and / or advance the project.

The AdvanTx team


Email: [email protected]

Source link

About Bernice Dyer

Check Also

NC Teach for America: – EducationNC

The following is part of my monthly column, One Day and One Goal: Expanding opportunity …